DelveInsight's 'Night Vision Disturbances (NVD) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Night Vision Disturbances (NVD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2030
The DelveInsight Night Vision Disturbances (NVD) epidemiology report gives a thorough understanding of the Night Vision Disturbances (NVD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Night Vision Disturbances (NVD) in the US, Europe, and Japan. The report covers the detailed information of the Night Vision Disturbances (NVD) epidemiology scenario in seven major countries (US, EU5, and Japan).
The Night Vision Disturbances (NVD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Night Vision Disturbances (NVD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Night Vision Disturbances (NVD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Night Vision Disturbances (NVD) epidemiology covered in the report provides historical as well as forecasted Night Vision Disturbances (NVD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Night Vision Disturbances (NVD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
1. Key Insights
2. Executive Summary of Night Vision Disturbances (NVD)
3. Night Vision Disturbances (NVD) : Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Night Vision Disturbances (NVD) Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Night Vision Disturbances (NVD) Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Night Vision Disturbances (NVD) Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Night Vision Disturbances (NVD) Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Night Vision Disturbances (NVD) Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Night Vision Disturbances (NVD) Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Night Vision Disturbances (NVD) Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Night Vision Disturbances (NVD) Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Night Vision Disturbances (NVD) Treatment and Management
6.2. Night Vision Disturbances (NVD) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Night Vision Disturbances (NVD) Epidemiology in 7MM (2017-2030)
Table 2 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Night Vision Disturbances (NVD) Epidemiology in the United States (2017-2030)
Table 4 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Night Vision Disturbances (NVD) Epidemiology in Germany (2017-2030)
Table 6 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Night Vision Disturbances (NVD) Epidemiology in France (2017-2030)
Table 8 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Night Vision Disturbances (NVD) Epidemiology in Italy (2017-2030)
Table 10 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Night Vision Disturbances (NVD) Epidemiology in Spain (2017-2030)
Table 12 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Night Vision Disturbances (NVD) Epidemiology in the United Kingdom (2017-2030)
Table 14 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Night Vision Disturbances (NVD) Epidemiology in Japan (2017-2030)
Table 16 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Night Vision Disturbances (NVD) Epidemiology in 7MM (2017-2030)
Figure 2 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Night Vision Disturbances (NVD) Epidemiology in the United States (2017-2030)
Figure 4 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Night Vision Disturbances (NVD) Epidemiology in Germany (2017-2030)
Figure 6 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Night Vision Disturbances (NVD) Epidemiology in France (2017-2030)
Figure 8 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Night Vision Disturbances (NVD) Epidemiology in Italy (2017-2030)
Figure 10 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Night Vision Disturbances (NVD) Epidemiology in Spain (2017-2030)
Figure 12 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Night Vision Disturbances (NVD) Epidemiology in the United Kingdom (2017-2030)
Figure 14 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Night Vision Disturbances (NVD) Epidemiology in Japan (2017-2030)
Figure 16 Night Vision Disturbances (NVD) Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report